LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Indirect Inhibition of Overexpressed Androgen Receptor Activity Halts Growth of Castration-Resistant Prostate Cancer

By LabMedica International staff writers
Posted on 13 Apr 2016
Print article
Image: Space-filling model showing the crystallographic structure of the ligand binding domain of the ROR-gamma (receptor–related orphan receptor gamma) protein (Photo courtesy of Wikimedia Commons).
Image: Space-filling model showing the crystallographic structure of the ligand binding domain of the ROR-gamma (receptor–related orphan receptor gamma) protein (Photo courtesy of Wikimedia Commons).
Cancer researchers have shown that by suppressing the nuclear receptor protein ROR-gamma with small-molecule compounds they could reduce androgen receptor levels in castration-resistant prostate cancer and stop tumor growth.

The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the factors that cause AR overexpression have not been thoroughly studied.

Investigators at the University of California, Davis (USA) worked with prostate cancer cell cultures and mouse xenograft models. They reported in the March 28, 2016, online edition of the journal Nature Medicine that retinoic acid receptor–related orphan receptor gamma (ROR-gamma) was overexpressed and amplified in metastatic CRPC tumors, and that ROR-gamma drove AR expression in the tumors. ROR-gamma recruited the proteins nuclear receptor coactivators 1 and 3 (NCOA1 and NCOA3) to an AR–ROR response element (RORE) to stimulate AR gene transcription.

The investigators showed that drugs that blocked ROR-gamma suppressed the expression of both AR and its variant AR-V7 in prostate cancer cell lines and tumors. Drugs that blocked ROR-gamma suppressed tumor growth in multiple AR-expressing xenograft prostate cancer models. The drugs were not effective in AR-negative models. In addition, ROR-gamma blockers effectively sensitized CRPC tumors to the drug enzalutamide, without overt toxicity, in mice.

"This is a new target and a totally new way of hitting prostate cancer," said senior author Dr. Hongwu Chen, professor of biochemistry and molecular medicine at the University of California, Davis. "This strategy targets the root cause of the problem - the overexpression of the AR gene and its protein."

"ROR-gamma has been extensively studied as a target for rheumatoid arthritis, inflammatory bowel disease, psoriasis, and other autoimmune conditions," said Dr. Chen. "Some of the drugs are orally available and have been found to be safe in early clinical trials. They could be a great help for patients with advanced prostate cancer."

Related Links:

University of California, Davis


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more